{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:01:42Z","timestamp":1784811702518,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["105604\/Z\/14\/Z"],"award-info":[{"award-number":["105604\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003784","name":"Great Ormond Street Hospital for Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.omtn.2020.10.028","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T09:53:55Z","timestamp":1603446835000},"page":"1191-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy"],"prefix":"10.1016","volume":"22","author":[{"given":"Virginie","family":"Mariot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Charlotte","family":"Marsollier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hourd\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Voit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dumonceaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2020.10.028_bib1","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1093\/hmg\/ddu129","article-title":"Nuclear protein spreading: implication for pathophysiology of neuromuscular diseases","volume":"23","author":"Ferreboeuf","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.10.028_bib2","first-page":"1662","article-title":"Facioscapulohumeral muscular dystrophies","volume":"25","author":"Wagner","year":"2019","journal-title":"Continuum (Minneap. Minn.)"},{"key":"10.1016\/j.omtn.2020.10.028_bib3","doi-asserted-by":"crossref","first-page":"e1001181","DOI":"10.1371\/journal.pgen.1001181","article-title":"Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene","volume":"6","author":"Snider","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2020.10.028_bib4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/WCO.0b013e328357f22d","article-title":"Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation","volume":"25","author":"van der Maarel","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.omtn.2020.10.028_bib5","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtn.2020.10.028_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.devcel.2011.11.013","article-title":"DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy","volume":"22","author":"Geng","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2020.10.028_bib7","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1093\/hmg\/ddt272","article-title":"Dysregulation of 4q35- and muscle-specific genes in fetuses with a short D4Z4 array linked to facio-scapulo-humeral dystrophy","volume":"22","author":"Broucqsault","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.10.028_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/hmg\/ddt409","article-title":"DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles","volume":"23","author":"Ferreboeuf","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.10.028_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/jpm10030073","article-title":"DUX4 expression in FSHD muscles: focus on its mRNA regulation","volume":"10","author":"Sidlauskaite","year":"2020","journal-title":"J.\u00a0Pers. Med."},{"key":"10.1016\/j.omtn.2020.10.028_bib10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/j.2040-4603.2017.tb00779.x","article-title":"Facioscapulohumeral muscular dystrophy","volume":"7","author":"DeSimone","year":"2017","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.omtn.2020.10.028_bib11","doi-asserted-by":"crossref","first-page":"e26820","DOI":"10.1371\/journal.pone.0026820","article-title":"The FSHD atrophic myotube phenotype is caused by DUX4 expression","volume":"6","author":"Vanderplanck","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2020.10.028_bib12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ana.22275","article-title":"DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in\u00a0vivo","volume":"69","author":"Wallace","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2020.10.028_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/hmg\/dds467","article-title":"Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy","volume":"22","author":"Mitsuhashi","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.10.028_bib14","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","article-title":"Antisense targeting of 3\u2032 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach","volume":"25","author":"Marsollier","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.10.028_bib15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2020.10.028_bib16","doi-asserted-by":"crossref","first-page":"eaaw7099","DOI":"10.1126\/sciadv.aaw7099","article-title":"Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy","volume":"5","author":"DeSimone","year":"2019","journal-title":"Sci. Adv"},{"key":"10.1016\/j.omtn.2020.10.028_bib17","doi-asserted-by":"crossref","first-page":"eaaw7781","DOI":"10.1126\/sciadv.aaw7781","article-title":"A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death","volume":"5","author":"Bosnakovski","year":"2019","journal-title":"Sci. Adv"},{"key":"10.1016\/j.omtn.2020.10.028_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.119.259663","article-title":"Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy","volume":"370","author":"Oliva","year":"2019","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.omtn.2020.10.028_bib19","doi-asserted-by":"crossref","first-page":"E2886","DOI":"10.3390\/jcm9092886","article-title":"Therapeutic strategies targeting DUX4 in FSHD","volume":"9","author":"Le Gall","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omtn.2020.10.028_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13395-016-0080-z","article-title":"DNA-binding sequence specificity of DUX4","volume":"6","author":"Zhang","year":"2016","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2020.10.028_bib21","doi-asserted-by":"crossref","first-page":"e64691","DOI":"10.1371\/journal.pone.0064691","article-title":"DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells","volume":"8","author":"Sharma","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2020.10.028_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.adgen.2014.10.004","article-title":"Noncoding oligonucleotides: the belle of the ball in gene therapy","volume":"89","author":"Shum","year":"2015","journal-title":"Adv. Genet."},{"key":"10.1016\/j.omtn.2020.10.028_bib23","first-page":"79","article-title":"Controversies in the cellular pharmacology of oligodeoxynucleotides","volume":"209","author":"Stein","year":"1997","journal-title":"Ciba Found. Symp."},{"key":"10.1016\/j.omtn.2020.10.028_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood.V98.4.995","article-title":"The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5\u2032-nucleotidase","volume":"98","author":"Koziolkiewicz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2020.10.028_bib25","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1038\/emboj.2008.201","article-title":"An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies","volume":"27","author":"Bosnakovski","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.omtn.2020.10.028_bib26","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1242\/jcs.205427","article-title":"The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain","volume":"130","author":"Bosnakovski","year":"2017","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtn.2020.10.028_bib27","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/s41467-017-01200-4","article-title":"PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle","volume":"8","author":"Banerji","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2020.10.028_bib28","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/hmg\/ddz043","article-title":"PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level","volume":"28","author":"Banerji","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.10.028_bib29","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1242\/jcs.02908","article-title":"Pax7 and myogenic progression in skeletal muscle satellite cells","volume":"119","author":"Zammit","year":"2006","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtn.2020.10.028_bib30","doi-asserted-by":"crossref","first-page":"14038","DOI":"10.1038\/mtm.2014.38","article-title":"Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells","volume":"1","author":"Arnett","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2020.10.028_bib31","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41467-017-00924-7","article-title":"Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle","volume":"8","author":"Novak","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2020.10.028_bib32","first-page":"257","article-title":"E2F decoy oligodeoxynucleotide ameliorates cartilage invasion by infiltrating synovium derived from rheumatoid arthritis","volume":"18","author":"Tomita","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.omtn.2020.10.028_bib33","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1080\/15384101.2015.1104436","article-title":"Ablation of the transcription factors E2F1-2 limits neuroinflammation and associated neurological deficits after contusive spinal cord injury","volume":"14","author":"Wu","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.omtn.2020.10.028_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/07357907.2013.861471","article-title":"Blockage of STAT3 signaling pathway with a decoy oligodeoxynucleotide inhibits growth of human ovarian cancer cells","volume":"32","author":"Liu","year":"2014","journal-title":"Cancer Invest."},{"key":"10.1016\/j.omtn.2020.10.028_bib35","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2015-08-665604","article-title":"Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2020.10.028_bib36","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nm0897-894","article-title":"In\u00a0vivo transfection of cis element \u201cdecoy\u201d against nuclear factor-\u03baB binding site prevents myocardial infarction","volume":"3","author":"Morishita","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2020.10.028_bib37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1089\/hum.2013.106","article-title":"Inhibitory effect of nuclear factor-\u03baB decoy oligodeoxynucleotide on liver fibrosis through regulation of the epithelial-mesenchymal transition","volume":"25","author":"Kim","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2020.10.028_bib38","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/2159-8290.CD-12-0191","article-title":"First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy","volume":"2","author":"Sen","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2020.10.028_bib39","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2020.10.028_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2020.10.028_bib41","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41598-020-57893-z","article-title":"Capsid-specific removal of circulating antibodies to adeno-associated virus vectors","volume":"10","author":"Bertin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2020.10.028_bib42","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2020.10.028_bib43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ana.24446","article-title":"Correlation between low FAT1 expression and early affected muscle in facioscapulohumeral muscular dystrophy","volume":"78","author":"Mariot","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2020.10.028_bib44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin. Chem."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253120303401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253120303401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:13:56Z","timestamp":1784808836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253120303401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":44,"alternative-id":["S2162253120303401"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2020.10.028","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2020.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}]}}